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Summary
Background Stenting is an alternative to endarterectomy for treatment of carotid artery stenosis, but long-term eﬃ  cacy 
is uncertain. We report long-term data from the randomised International Carotid Stenting Study comparison of 
these treatments.
Methods Patients with symptomatic carotid stenosis were randomly assigned 1:1 to open treatment with stenting or 
endarterectomy at 50 centres worldwide. Randomisation was computer generated centrally and allocated by telephone 
call or fax. Major outcomes were assessed by an independent endpoint committee unaware of treatment assignment. 
The primary endpoint was fatal or disabling stroke in any territory after randomisation to the end of follow-up. 
Analysis was by intention to treat ([ITT] all patients) and per protocol from 31 days after treatment (all patients in 
whom assigned treatment was completed). Functional ability was rated with the modiﬁ ed Rankin scale. This study is 
registered, number ISRCTN25337470.
Findings 1713 patients were assigned to stenting (n=855) or endarterectomy (n=858) and followed up for a median of 
4∙2 years (IQR 3∙0–5∙2, maximum 10∙0). Three patients withdrew immediately and, therefore, the ITT population 
comprised 1710 patients. The number of fatal or disabling strokes (52 vs 49) and cumulative 5-year risk did not diﬀ er 
signiﬁ cantly between the stenting and endarterectomy groups (6∙4% vs 6∙5%; hazard ratio [HR] 1∙06, 95% CI 0∙72–1∙57, 
p=0∙77). Any stroke was more frequent in the stenting group than in the endarterectomy group (119 vs 72 events; ITT 
population, 5-year cumulative risk 15∙2% vs 9∙4%, HR 1∙71, 95% CI 1∙28–2∙30, p<0∙001; per-protocol population, 5-year 
cumulative risk 8∙9% vs 5∙8%, 1∙53, 1∙02–2∙31, p=0∙04), but were mainly non-disabling strokes. The distribution of 
modiﬁ ed Rankin scale scores at 1 year, 5 years, or ﬁ nal follow-up did not diﬀ er signiﬁ cantly between treatment groups.
Interpretation Long-term functional outcome and risk of fatal or disabling stroke are similar for stenting and 
endarterectomy for symptomatic carotid stenosis.
Funding Medical Research Council, Stroke Association, Sanoﬁ -Synthélabo, European Union.
Copyright © Bonati et al. Open Access article distributed under the terms of CC BY.
Introduction
Atherosclerotic stenosis of the internal carotid artery 
causes 10–15% of all strokes. Carotid endarterectomy 
lowers the long-term risk of stroke in patients with 
symptomatic carotid stenosis.1,2 Carotid artery stenting 
has emerged as an alternative to endarterectomy. In 
randomised trials comparing stenting with endarterec-
tomy for symptomatic carotid stenosis, stenting was 
associated with a higher risk of procedure-related 
stroke, particularly in elderly patients, but with lower 
risks of myocardial infarction, cranial nerve palsy, and 
access site haematoma.3–6 A systematic review showed 
that the increase in procedure-related risk was driven 
by non-disabling stroke, with no evidence for a 
diﬀ erence in rates of major or disabling stroke or death 
between the treatments.7 The International Carotid 
Stenting Study (ICSS) was the largest of the trials 
assessed that compared stenting with endarterectomy 
in patients with symptomatic stenosis, and we reported 
an interim safety analysis of outcomes within 120 days 
of randomisation in 2010.5 At that time the eﬃ  cacy of 
stenting and endarterectomy in preventing stroke and 
maintaining patency of the carotid artery beyond 
2–4 years after treatment and long-term functional 
outcome was unclear. Here we report the primary 
analysis of ICSS long-term outcomes up to 10 years 
after randomisation.
Methods
Study design and patients
ICSS was an international, multicentre, randomised 
clinical trial of endarterectomy versus stenting for the 
treatment of symptomatic carotid stenosis. Details on 
eligibility criteria for centres and patients, random-
isation, and treatment have been reported previously.5,8 
In brief, patients aged older than 40 years with 
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symptomatic atherosclerotic carotid stenosis causing at 
least 50% reduction in carotid artery lumen diameter and 
who were deemed equally suited for both treatments 
were eligible. Patients who had had a major stroke or 
previous treatment with carotid stenting or 
endarterectomy, had contraindications to stenting or 
surgery, stenosis caused by non-athero sclerotic disease 
or life expectancy of less than 2 years, or who were 
scheduled for major surgery within 1 month were 
excluded. ICSS was approved by the Northwest 
Multicentre Research Ethics Committee in the UK. 
Individual participating centres obtained site-speciﬁc 
approval from their local ethics committees. All patients 
provided written informed consent.
Randomisation and masking
Patients were assigned to undergo stenting or 
endarterectomy in a 1:1 ratio. Randomisation was com-
puter generated centrally by the Oxford Clinical Trials 
Service Unit, Oxford, UK, and allocations were obtained by 
telephone or fax from staﬀ  who were not involved in other 
parts of the trial. Randomisation was stratiﬁ ed by centre 
with minimisation for sex, age, side of stenosis, and 
occlusion of the contralateral carotid artery. Patients and 
investi gators were not masked to treatment assignment.
Procedures and follow-up
Stents and cerebral protection devices were chosen at the 
discretion of the interventionist, but had to be CE marked 
1713 patients randomised
855 assigned to stenting
2 withdrew all consent immediately 
after randomisation
853 analysed by intention to treat from 
randomisation until end of follow-up
9 crossed over to endarterectomy
2 anatomy unsuitable
3 medical contraindications
1 refused treatment
3 other reasons
16 underwent no procedure
1 disabling stroke before
intended procedure
5 artery occluded
3 artery less than 50% stenosed
1 anatomy unsuitable
3 other medical contraindications
3 other reasons
828 stenting initiated
76 did not complete treatment
64 stenting aborted†
10 fatal events 
before 30 days‡
2 lost to follow-up 
before 30 days‡
27 no ultrasound 
after procedure*
737 analysed for restenosis 
from date of procedure 
until last ultrasound
752 analysed per-protocol 
from 31 days after procedure 
to end of follow-up
858 assigned to endarterectomy
1 withdrew all consent immediately 
after randomisation
857 analysed by intention to treat from 
randomisation until end of follow-up
15 crossed over to stenting
1 anatomy unsuitable
6 medical contraindications
4 refused treatment
4 other reasons
21 underwent no procedure
2 died before intended procedure
3 disabling stroke before 
intended procedure
9 artery occluded
1 artery less than 50% stenosed
3 medical contraindications
1 refused treatment
2 other reasons
821 endarterectomy initiated
10 did not complete treatment
2 endarterectomy aborted†
4 fatal events 
before 30 days‡
4 lost to follow-up 
before 30 days‡
26 no ultrasound
after procedure*
811 analysed per-protocol 
from 31 days after procedure 
to end of follow-up
793 analysed for restenosis 
from date of procedure 
until last ultrasound
Figure 1: Trial proﬁ le
Numbers at screening and excluded before enrolment were not recorded. ITT=intention to treat. *Excluded from the restenosis analysis. †Excluded from per-protocol 
analysis and restenosis analysis. ‡Excluded from per-protocol analysis. 
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and approved by the steering committee. Surgeons were 
free to perform standard or eversion endarterectomy 
under local or general anaesthesia, with or without the 
use of shunts and patches. All patients received medical 
care, including antiplatelet therapy, or anticoagulation if 
indicated, and medical risk factors, such as hypertension, 
smoking, and hyperlipidaemia, were monitored.
Patients attended follow-up visits 30 days after 
treatment (end of the procedural period), 6 months after 
randomisation, and annually thereafter. Functional 
ability was measured with the modiﬁ ed Rankin scale at 
the time of randomisation, at each follow-up visit, and 
30 days after any stroke outcome event.9 Duplex carotid 
ultra sonography was used at each follow-up visit to 
assess the degree of carotid artery stenosis. Follow-up 
was initially planned for 5 years but was extended to 
10 years in patients who were able and willing to 
continue.
Outcome events and endpoints
Major outcome events were adjudicated by an 
independent endpoint committee that was unaware of 
treatment allocations. Stroke was deﬁ ned as a rapidly 
developing clinical syndrome of focal disturbance of 
cerebral function that lasted more than 24 h or led to 
death within 24 h with no other apparent non-vascular 
cause. Stroke was classiﬁ ed as fatal if the patient died 
within 30 days of onset and as disabling if the modiﬁ ed 
Rankin scale score had increased to 3 or more at 30 days 
after onset. Ipsilateral stroke was deﬁ ned as infarction or 
haemorrhage in the territory of the anterior or middle 
cerebral artery on the side of the randomised artery. A 
procedural event was deﬁ ned as one that occurred at any 
time from the start of surgery or stenting (day 0) to day 
30 after treatment.
The database manager at the trial oﬃ  ce (RLF) 
monitored procedural outcome events. If two con secutive 
major events or a cumulative major event rate of more 
than 10% within 30 days of treatment were seen in the 
same arm of the study within a study centre, an 
assessment of the events was triggered. The anonymised 
records of the relevant outcome events were submitted to 
the chairman of the data monitoring committee who 
recommend further action, such as suspending 
randomisation at the centre.
The degree of carotid stenosis during follow-up was 
determined centrally from ultrasound ﬂ ow velocity data, 
on the basis of predeﬁ ned criteria (peak systolic velocity 
and end-diastolic velocity of the internal carotid artery 
and peak systolic velocity of the common carotid artery).10 
The assessor (LHB) was unaware of treatment allocations 
and dates of ultrasound follow-up. Results of carotid 
imaging studies ordered outside regular follow-up at the 
discretion of the treating clinicians, for instance for 
recurrent symptoms, were also assessed centrally. 
Restenosis was deﬁ ned as any residual or recurrent 
stenosis of at least 70% or occlusion of the carotid artery 
Stenting 
(n=853)
Endarterectomy 
(n=857)
Age (years) 70 (9) 70 (9)
Male sex 601 (70%) 606 (71%)
Vascular risk factors
Treated hypertension 587 (69%) 596 (70%)
Systolic blood pressure (mm Hg) 147 (24) 146 (24)
Diastolic blood pressure (mm Hg) 79 (12) 78 (13)
Cardiac failure 23 (3%) 47 (5%)
Angina in past 6 months 83 (10%) 77 (9%)
Previous myocardial infarction 151 (18%) 156 (18%)
Previous CABG 109 (13%) 116 (14%)
Atrial ﬁ brillation 57 (7%) 59 (7%)
Other cardiac embolic source 19 (2%) 16 (2%)
Type 2 diabetes 134 (16%) 147 (17%)
Type 1 diabetes 50 (6%) 41 (5%)
Peripheral artery disease 139 (16%) 136 (16%)
Current smoker 205 (24%) 198 (23%)
Ex-smoker 408 (48%) 424 (49%)
Treated hyperlipidaemia 522 (61%) 563 (66%)
Total serum cholesterol (mmol/L) 4·8 (1·3) 4·9 (1·3)
Degree of symptomatic carotid 
stenosis*
50–69% 92 (11%) 76 (9%)
70–99% 761 (89%) 781 (91%)
Degree of contralateral carotid 
stenosis*
<50% 565 (66%) 561 (65%)
50–69% 128 (15%) 142 (17%)
70–99% 105 (12%) 110 (13%)
Occluded 49 (6%) 37 (4%)
Unknown 6 (1%) 7 (1%)
Most recent ipsilateral event†
Ischaemic hemispheric stroke 393 (46%) 376 (44%)
Transient ischaemic attack 273 (32%) 303 (35%)
Retinal infarct 26 (3%) 23 (3%)
Amaurosis fugax 148 (17%) 142 (17%)
Unknown 13 (2%) 13 (2%)
Event <6 months before 
randomisation
826 (97%) 816 (95%)
Event 6–12 months before 
randomisation‡
27 (3%) 36 (4%)
Modiﬁ ed Rankin score at 
randomisation
0–2 756 (89%) 744 (87%)
3–5§ 81 (10%) 99 (12%)
Unknown 16 (2%) 14 (2%)
Data are mean (SD) or number (%). Some totals do not add up to 100% because 
of rounding. CABG=coronary artery bypass graft. *Degree of stenosis reported 
by randomising centre according to the measure used in the North American 
Symptomatic Carotid Endarterectomy Trial1 or a non-invasive equivalent. †If 
two events were reported on the same day, that higher up in the order of 
events as listed was counted. ‡In three patients the event was more than 
12 months before randomisation and in two the date was unknown. §Some 
modiﬁ ed Rankin scores ≥3 were caused by non-stroke disability.
Table 1: Baseline characteristics 
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during follow-up. No correction was made for the 
presence of a stent when measuring stenosis.
The prespeciﬁ ed primary endpoint was fatal or 
disabling stroke in any territory after randomisation. 
Secondary endpoints were all-cause death, any stroke, 
and combined procedural stroke in any territory, 
procedural death, and ipsilateral stroke during follow-up. 
The primary analysis was done in all patients assigned to 
either treatment, irrespective of treatment received 
(intention-to-treat [ITT] population). A per-protocol 
analysis of non-procedural events was done from 
31 days after treatment to the end of follow-up in patients 
who started and completed their allocated treatment 
(per-protocol population). Rates of ipsilateral restenosis 
were analysed from the date of the treatment in patients 
who started and completed their allocated treatment.
Statistical analysis
We estimated that the primary endpoint would be seen 
in 5·7% of patients in the stenting and endarterectomy 
groups at 5 years’ follow-up. We therefore calculated that 
a sample size of 1500 patients enrolled at experienced 
centres would be suﬃ  cient to assess the absolute risk 
diﬀ erence between groups as measured with a 95% CI of 
2·5 percentage points in either direction. In the interim 
safety analysis no signiﬁ cant diﬀ erence in risk was 
seen between stenting and endarterectomy in supervised 
centres (n=199) and experienced centres (n=1511).5 There-
fore, we combined the results from supervised and 
experienced centres in the long-term analysis.
Kaplan-Meier estimates of cumulative risk at 1 year 
and 5 years after randomisation (ITT population) or 
treatment (per-protocol population) and absolute risk 
diﬀ erences between treatment groups, with 95% CIs, 
were calculated. Log-rank tests were used to compare 
the Kaplan-Meier cumulative incidence curves. Cox’s 
proportional hazard models were used to calculate 
hazard ratios (HRs) and 95% CIs for outcomes, with 
endarterectomy as the reference group and using all 
data to the end of follow-up. The proportionality for 
Cox’s models was tested with Schoenfeld residuals and 
conﬁ rmed no signiﬁ cant departures from the pro-
portionality assumption. We did sensitivity analyses for 
the main outcomes, as prespeciﬁ ed, with adjustment 
for the variables used to condition randomisation 
(centre, age, sex, side of stenosis, and contralateral 
occlusion). As the number of events was larger in the 
ITT than in the per-protocol population, we additionally 
adjusted the ITT analysis for the prespeciﬁ ed variables 
treated hypertension, treated hyperlipidaemia, diabetes, 
degree of ipsilateral stenosis, and type of latest event 
before randomisation. Censoring was assumed to be 
non-informative.
The restenosis outcome was interval-censored and, 
therefore, was analysed with a generalised non-linear 
model that assumes proportional hazards and allows the 
treatment eﬀ ect parameter estimate to be interpreted as a 
log HR.11 The p value for treatment eﬀ ect was calculated 
with a likelihood ratio test. Life-table analyses were used 
to estimate the cumulative incidence of restenosis at 
1 year and 5 years after treatment.
Interaction tests were done with Cox’s proportional 
hazard models to investigate whether the treatment 
eﬀ ect for the primary endpoint and for procedure-related 
stroke, death, or ipsilateral stroke during follow-up 
diﬀ ered between subgroups of patients on the basis of 
baseline characteristics. Functional ability was compared 
in the ITT population at 1 year, 5 years, and ﬁ nal follow-
up across the entire range of the modiﬁ ed Rankin scale 
scores, with the permutation test described by Howard 
and colleagues.12 Drug treatments and blood pressure at 
1 year and 5 years were compared, respectively, with the 
χ² test and t tests (Satterthwaite approximation) at each 
timepoint. All reported p values are two-sided, with 
values less than 0∙05 taken to be signiﬁ cant. No 
adjustment was made for multiple comparisons. This 
study is registered, number ISRCTN25337470.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
Stenting (n=853) Endarterectomy (n=857) Hazard ratio*
(95% CI)
Absolute risk diﬀ erence (95% CI)
Number of 
events*
Cumulative 
1-year risk (SE)†
Cumulative 
5-year risk (SE)†
Number of 
events*
Cumulative 
1-year risk (SE)†
Cumulative 
5-year risk (SE)†
At 1 year At 5 years
Fatal or disabling 
stroke (primary 
outcome measure)
52 3·9% (0·7) 6·4% (0·9) 49 3·2% (0·6) 6·5% (1·0) 1·06 (0·72 to 1·57) 0·7% (–1·0 to 2·5) –0·2% (–2·8 to 2·5)
Any stroke 119 9·5% (1·0) 15·2% (1·4) 72 5·1% (0·8) 9·4% (1·1) 1·71 (1·28 to 2·30)‡ 4·4% (1·9 to 6·9) 5·8% (2·4 to 9·3)
Procedural stroke or 
procedural death or 
ipsilateral stroke 
during follow-up
95 9·0% (1·0) 11·8% (1·2) 57 4·7% (0·7) 7·2% (0·9) 1·72 (1·24 to 2·39)§ 4·2% (1·9 to 6·6) 4·6% (1·6 to 7·6)
All-cause death 153 4·9% (0·7) 17·4% (1·5) 129 2·3% (0·5) 17·2% (1·5) 1·17 (0·92 to 1·48) 2·6% (0·8 to 4·4) 0·2% (–4·0 to 4·4)
*Calculated as the ﬁ rst relevant event between randomisation and the end of follow-up. †Calculated from randomisation onwards. ‡p<0·001. §p<0·01. 
Table 2: Intention-to-treat analysis of cumulative risks and hazard ratios of main outcome events 
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G
0
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793
1
638
681
2
547
611
3
455
483
4
Follow-up (years) Follow-up (years)
347
330
5
190
187
6
91
89
7
44
45
H
HR 1·06 (95% CI 0·72–1·57), p=0·77 HR 1·71 (95% CI 1·28–2·30), p=0·0003
HR 1·72 (95% CI 1·24–2·39), p=0·001 HR 1·17 (95% CI 0·92–1·48), p=0·19
HR 1·53 (95% CI 1·02–2·31), p=0·039 HR 1·29 (95% CI 0·74–2·24), p=0·36
HR 1·92 (95% CI 1·04–3·53), p=0·033 HR 1·25 (95% CI 0·89–1·75), p=0·20
CAS
CEA
3·9%
3·2%
6·4%
6·5%
9·5%
5·1%
15·2%
9·4%
9·0%
4·7%
11·8%
7·2% 4·9%
2·3%
17·4%
17·2%
2·9%
1·8%
8·9%
5·8% 1·4%
1·1%
4·7%
3·4%
1·4%
0·5%
4·6%
2·5%
6·9%
5·3%
10·8%
8·6%
Figure 2: Kaplan-Meier 
estimates of cumulative 
incidence for major 
outcomes
(A) Fatal or disabling stroke. 
(B) Any stroke. (C) Procedural 
stroke or procedural death or 
ipsilateral stroke during 
follow-up. (D) All-cause death. 
(E) Any stroke more than 
30 days after treatment. 
(F) Ipsilateral stroke more than 
30 days after treatment. 
(G) Contralateral carotid or 
vertebrobasilar stroke more 
than 30 days after treatment. 
(H) Ipsilateral severe (at least 
70%) carotid stenosis after 
completed treatment, 
generated by life-table 
analysis. Panels A–D show 
results for the intention-to-
treat population, E–G for the 
per-protocol population from 
30 days after treatment, 
and H for the per-protocol 
population from treatment. 
Percentage values are the 
estimated cumulative 
incidence at 1 year and 5 years. 
Graphs stop at 7 years’ 
follow-up because numbers 
beyond that time were less 
than 100, but analyses were 
based on all follow-up data 
(maximum 10 years). 
HR=hazard ratio. CAS=carotid 
stenting. CEA=carotid 
endarterectomy. 
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all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
1713 patients were recruited at 50 centres in Europe, 
Australia, New Zealand, and Canada (appendix) between 
May, 2001, and October, 2008. 855 patients were randomly 
assigned to stenting and 858 to endarterectomy. Three 
patients withdrew before treatment and, therefore, 
1710 patients comprised the ITT population (ﬁ gure 1). 
The trial was terminated in 2011. Patients were followed 
up for a median of 4∙2 years (IQR 3·0–5·2, maximum 
10·0) after randomisation, yielding 7354 patient-years of 
follow-up. Length of follow-up did not diﬀ er between 
treatment groups (appendix).
Patients’ characteristics at baseline were similar in the 
two groups (table 1). Technical information for the 
stenting and endarterectomy procedures is provided in 
the appendix. The proportions of patients taking 
antiplatelet agents or lipid-lowering medications were 
similar in the two treatment groups for most of the 
trial period. At 1 year slightly more patients in the 
endarterectomy group than in the stenting group were 
taking antihypertensive medications (75% vs 71%, 
p=0∙088) and had lower systolic and diastolic blood 
pressures (144 vs 147 mm Hg, p=0∙011 and 78 vs 
79 mm Hg, p=0∙035, respectively; appendix). At 5 years 
of follow-up more patients in the stenting group were 
receiving antihypertensive treatment (83% vs 76%, 
p=0∙017) and blood pressures no longer diﬀ ered.
In the ITT population, the primary endpoint of fatal or 
disabling stroke between randomisation and end of 
follow-up was seen in 52 of 853 patients in the stenting 
group (cumulative 5-year risk 6∙4%), and in 49 of 
857 patients in the endarterectomy group (cumulative 
5-year risk 6∙5%). No diﬀ erence was seen between groups 
in time to ﬁ rst event (table 2, ﬁ gure 2). In the comparison 
of secondary outcome events in this population, 
signi ﬁ cantly more patients in the stenting group had any 
stroke than in the endarterectomy group (p=0∙0003, 
table 2), but the diﬀ erence was attributable mainly to an 
excess of non-disabling stroke (73 vs 27 events, appendix). 
The combined outcome of procedure-related stroke or 
procedure-related death or ipsilateral stroke during 
follow-up was also more frequent in the stenting group 
than in the endarterectomy group (p=0∙001, table 2). All-
cause mortality did not diﬀ er signiﬁ cantly between 
treatment groups (p=0∙19, table 2). Other procedural 
events and those occurring during the follow-up period 
are described in the appendix).
Exploratory subgroup analyses showed that none of the 
patients’ baseline characteristics signiﬁ cantly altered the 
risk of primary or secondary endpoints (appendix). The 
HR for a secondary endpoint (procedural stroke or 
procedural death, or ipsilateral stroke during follow-up) 
was lower for patients treated at larger centres (enrolling 
50 or more patients in the trial) than for those treated at 
smaller centres (HR 1∙27, 95% CI 0∙83–1∙93 vs 2∙77, 
1∙60–4∙77, pinteraction=0·024; appendix).
Monitoring of adverse events led to concern about the 
stenting results of two investigators at two diﬀ erent 
supervised centres. These investigators were stopped 
from treating further trial patients and the centres were 
suspended from randomisation. All the patients who had 
been allocated in these centres to stenting (n=11, ﬁ ve with 
disabling stroke or death) or endarterectomy (n=9, 
one with fatal stroke) were included in the analyses. 
Randomisation was restarted in one of the two centres 
when an interventionist experienced in stenting joined 
the team. Subgroup analysis showed no diﬀ erence in 
treatment eﬀ ects of stenting versus endarterectomy on 
primary and secondary endpoints between supervised 
centres (including the two stopped centres) and 
experienced centres (appendix).
Functional outcome measured by the distribution of 
modiﬁ ed Rankin scale scores at the end of follow-up 
did not diﬀ er signiﬁ cantly between treatment groups 
(ﬁ gure 3), nor was there any evidence of a diﬀ erence at 
1 year or 5 years after randomisation (appendix).
In the per-protocol population, no diﬀ erence was seen 
between treatment groups in the rates of fatal or disabling 
stroke (table 3). Of the secondary endpoint events, no 
signiﬁ cant diﬀ erence was seen between groups in 
ipsilateral stroke in the territory of the treated carotid 
artery, but stroke in any territory was more frequent in 
the stenting group than in the endarterectomy group 
(table 3, ﬁ gure 2). This diﬀ erence seemed to be driven by 
strokes occurring in the territory of the contralateral 
carotid artery or the vertebrobasilar circulation in patients 
treated with stents (cumulative 5-year risk 4∙6% vs 2∙5%, 
HR 1∙92, 95% CI 1∙04–3∙53, p=0∙033). Sensitivity 
analyses adjusted for the speciﬁ ed variables did not 
materially change the results.
No signiﬁ cant diﬀ erence was seen between groups in 
long-term rates of severe carotid restenosis (at least 70%) 
or occlusion (table 3, ﬁ gure 2). 
0 20 40 60 80 100
CAS
n=850
CEA
n=853
Proportion of patients (%)
0 1 2 3 4 5 6
Modified Rankin score
Figure 3: Functional ability measured by the modiﬁ ed Rankin scale at the end 
of follow-up*
A permutation test12 was done to compare scores at the end of follow-up 
between the two groups: unadjusted, p=0·49; adjusted for baseline modiﬁ ed 
Rankin scale score, p=0·24. CAS=carotid stenting. CEA=carotid endarterectomy. 
*Excludes seven patients (three CAS and four CEA) who had no scores recorded 
during follow-up and were still alive at their ﬁ nal visit.
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Discussion
The ICSS primary analysis shows that stenting is 
as eﬀ ective as endarterectomy in preventing fatal or 
disabling stroke in patients with symptomatic carotid 
stenosis up to 10 years after treatment. Carotid stenting 
was associated with a higher procedure-related and 
long-term risk of non-disabling stroke than endart-
erectomy, but functional ability did not diﬀ er overall. 
Both treatments seemed to be equally preventive against 
ipsilateral stroke and severe restenosis of the treated 
carotid artery.
Two smaller randomised trials of stenting versus 
endarterectomy for symptomatic carotid stenosis have 
reported mid-term follow-up. The EVA-3S trial13 showed 
no signiﬁ cant diﬀ erences in cumulative 4-year rates of 
fatal or disabling stroke between stenting and 
endarterectomy (6·3% vs 4∙0%). In the SPACE trial,14 
ipsilateral disabling stroke within 2 years or death or 
disabling stroke in any territory within 30 days of 
treatment were recorded in 5∙7% patients who underwent 
stenting and 4∙7% of patients who underwent 
endarterectomy. In CREST,6 which included patients with 
symptomatic and asymptomatic carotid stenosis, a 
slightly increased risk was seen for major ipsilateral 
stroke in the stenting group compared with that in the 
endarterectomy group up to 4 years after treatment (1∙4% 
vs 0∙5%; p=0∙05). Our data are consistent with these 
ﬁ ndings and show that the long-term risk of having a 
severe stroke remains low after either treatment.
The increased risk of procedure-related stroke of any 
severity with stenting was reported in our interim report 
on short-term outcomes of ICSS (excess risk of 3∙7% at 
30 days after treatment).5 The current analysis showed 
that the risk of stroke of any severity occurring in any 
territory during follow-up was also increased in the 
stenting group (excess risk 1∙1% compared with 
endarterectomy at 1 year, and 3∙1% at 5 years), but strokes 
were mainly non-disabling events. In CREST,6 patients 
who had minor strokes were reported to have reduced 
physical and mental health when assessed with the SF-36 
questionnaire. We used the modiﬁ ed Rankin scale, which 
does not directly capture subjective perception of 
wellbeing or subtle changes in physical or mental 
functioning. Assessment with the EQ-5D questionnaire 
in ICSS, however, showed no signiﬁ cant diﬀ erence in 
quality of life between the two treatment groups 
(unpublished). Thus, while we cannot rule out any 
diﬀ erences in long-term sequelae of stroke and other 
outcome events that are not captured by the modiﬁ ed 
Rankin scale or EQ-5D, the absolute diﬀ erence in the risk 
of any stroke is small, with the 47 additional strokes in the 
stenting group translating to one extra stroke (typically 
non-disabling) for every 156 patient-years of follow-up.
The diﬀ erence between treatment groups in risk of 
stroke after the procedural period was mainly attributable 
to strokes occurring in the contralateral carotid or 
vertebrobasilar territory in the stenting group. We have 
no conclusive explanation for this ﬁ nding. In ACST,15 
immediate endarterectomy reduced the number of 
strokes occurring in the ipsilateral and contralateral 
carotid territories. Patients treated by endarterectomy in 
CAVATAS16 also had fewer strokes in the contralateral 
carotid or vertebrobasilar territory than those who 
received endovascular treatment. Endarterectomy might, 
therefore, have a beneﬁ cial eﬀ ect in preventing strokes 
occurring outside the territory of the revascularised 
artery, but the underlying mechanism is unclear. A small 
substudy in the ICSS population showed that at 1 month 
after revascularisation, stenting and endarterectomy had 
diﬀ erent eﬀ ects on the diameters of segments of the 
circle of Willis.17 Whether this diﬀ erence had any eﬀ ect 
on collateral ﬂ ow to the opposite hemisphere is unclear, 
as neither cerebral perfusion nor long-term diﬀ erences 
were assessed. We cannot rule out the possibility that the 
diﬀ erence in non-ipsilateral strokes in ICSS represents a 
chance ﬁ nding because the number of events was small. 
Stenting (n=752) Endarterectomy (n=811) Hazard ratio* 
(95% CI)
Absolute risk diﬀ erence (95% CI)
Number of 
events*
Cumulative 
1-year risk (SE)*
Cumulative 
5-year risk (SE)*
Number of 
events*
Cumulative 
1-year risk (SE)*
Cumulative 
5-year risk (SE)*
At 1 year At 5 years
Fatal or disabling 
stroke
24 0·9% (0·4) 3·4% (0·8) 27 1·4% (0·4) 4·3% (0·9) 0·93 (0·53 to 1·60) –0·5% (–1·5 to 0·6) –0·9% (–3·2 to 1·4)
Any stroke 56 2·9% (0·6) 8·9% (1·2) 39 1·8% (0·5) 5·8% (1·0) 1·53 (1·02 to 2·31)† 1·1% (–0·4 to 2·6) 3·1% (0·0 to 6·2)
Ipsilateral carotid 
stroke
28 1·4% (0·4) 4·7% (0·9) 23 1·1% (0·4) 3·4% (0·8) 1·29 (0·74 to 2·24) 0·2% (–0·9 to 1·3) 1·2% (–1·1 to 3·6)
Contralateral carotid 
or vertebrobasilar 
stroke
29 1·4% (0·4) 4·6% (0·9) 16 0·5% (0·3) 2·5% (0·7) 1·92 (1·04 to 3·53)† 0·9% (–0·1 to 1·8) 2·1% (–0·2 to 4·3)
Severe carotid 
restenosis (≥70%) or 
occlusion
72/737 6·9% (1·0) 10·8% (1·3) 62/793 5·3% (0·8) 8·6% (1·1) 1·25 (0·89–1·75) 1·7% (–0·8 to 4·1) 2·2% (–1·1 to 5·4)
*Calculated from the end of the procedural period (30 days after completed treatment) for the ﬁ rst four outcomes and from immediately after completed treatment for the last outcome, until the end of 
follow-up. †p<0·05.
Table 3: Per-protocol analysis of cumulative risks and hazard ratios of main outcome events
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CAVATAS10 showed an excess risk of severe carotid 
restenosis or occlusion after endovascular treatment. The 
SPACE trial14 also reported higher rates of severe 
restenosis 2 years after treatment in the stenting group 
than in the endarterectomy group (10∙7% vs 4∙6%). By 
contrast, the rates of severe restenosis at 3 years did not 
diﬀ er between stenting and endarterectomy in the 
EVA-3S trial (3∙3% vs 2∙8%)18 or in CREST at 2 years 
(6∙0% vs 6∙3%).19 In ICSS we found no evidence of 
diﬀ erences in the long-term rates of severe restenosis or 
occlusion after stenting compared with endarterectomy 
(cumulative 5-year risk 10∙8% vs 8∙6%). The value for 
stenting, however, might overestimate the rate of 
restenosis because we used ﬂ ow velocity criteria to grade 
stenosis and made no correction for possible changes in 
elasticity of the stented artery.20 However, even if there 
were a true small diﬀ erence of a few percentage points in 
restenosis rates, it might not be clinically relevant. 
Further analysis to compare the rate of moderate (at least 
50%) restenosis between treatment groups and to 
investigate the association between restenosis and 
recurrent stroke is planned.
Subgroup analyses showed no signiﬁ cant eﬀ ects of 
patient-related baseline characteristics on the comparison 
of stenting and endarterectomy. However, ICSS was not 
powered to discover such eﬀ ects. In a separate analysis of 
ICSS restricted to patients who were randomised to and 
received stent treatment, age was an independent 
predictor of the risk of stroke, myocardial infarction, or 
death within 30 days of stenting, with a relative increase 
in risk of 17% for every 5 years of increasing age (risk ratio 
1∙17, 95% CI 1∙01–1∙37; unpublished). A previous pooled 
analysis of stent trials by the Carotid Stenting Trialists’ 
Collaboration (CTSC) also showed that the excess in 
procedural strokes associated with stenting for 
symptomatic carotid stenosis was limited to patients 
older than 70 years, whereas younger patients had very 
similar risks of stroke or death whether they were 
allocated stenting or endarterectomy.21 An update of those 
data, taking into account data from CREST,19 showed a 
positive interaction between age and the combined 
outcome of procedural stroke or death or ipsilateral stroke 
during follow-up, with the comparison showing no 
signiﬁ cant diﬀ erence between treatments in patients 
younger than 70 years and a signiﬁ cant risk increase in 
the stenting group compared with the endarterectomy 
group in patients older than 70 years.22
An excess risk of myocardial infarction and wound-
related complications associated with endarterec tomy was 
shown in a systematic review of randomised trials.7 The 
long-term results of ICSS in conjunction with the existing 
evidence, therefore, provides reassurance that stenting can 
be oﬀ ered as a durable procedure to patients with 
characteristics associated with similar or reduced risks of 
procedure-related stroke (eg, age younger than 70 years). 
Findings on brain imaging might be useful to consider, as 
we have shown previously that severe white-matter lesions 
on baseline CT or MRI are associated with an increased 
risk of stroke in patients who undergo carotid artery 
stenting.23 In patients who are suitable for both treatments, 
their preferences related to the diﬀ erent risks with the 
two procedures should also be taken into account.
Ongoing controversy surrounds the role of operator 
experience when comparing carotid stenting with 
endarterectomy. We found no diﬀ erence in relative 
hazards between stenting and endarterectomy when 
comparing supervised and experienced study centres. 
The HR for the combined outcome of procedural stroke 
or procedural death or ipsilateral stroke during follow-up 
was lower for centres that enrolled 50 or more patients 
than for smaller centres, which might indicate some 
eﬀ ect of procedural volume on technical expertise, but 
the point estimate still favoured endarterectomy in the 
larger centres. However, the previous pooled analysis of 
stent trials by the CSTC showed no signiﬁ cant diﬀ erence 
between high-volume and low-volume recruiting centres 
in relative risks of stroke or in death between stenting 
and endarterectomy in the ﬁ rst 120 days after 
randomisation.21 Therefore, we cannot rule out a chance 
eﬀ ect in the long-term ﬁ ndings of ICSS. A separate 
analysis by the CSTC showed that risks of 
procedure-related stroke or death decreased with 
increasing annual in-trial procedure volumes, which 
suggests that regular practice in carrying out the 
Panel: Research in context
Systematic review
We updated our Cochrane Collaboration review of angioplasty and stenting treatment 
versus endarterectomy for symptomatic carotid artery stenosis with the long-term 
outcomes of ICSS and those of the EVA-3S trial.7 Only randomised trials of primary carotid 
stenting (ie, routine placement of a stent) and reporting outcomes in symptomatic 
patients were included. The systematic review assessed combined stroke (any) or death in 
the procedural period or ipsilateral stroke thereafter until the end of follow-up, which was 
reported in all large randomised trials. The procedural period was that between 
randomisation and 30 days after the procedure or 30 days after randomisation in patients 
who did not undergo carotid revascularisation, to match the deﬁ nition in the seven 
reports assessed. The odds ratio of the combined outcome of any stroke or death in the 
procedural period or ipsilateral stroke thereafter was signiﬁ cantly greater in patients 
randomised to stenting than in those randomised to endarterectomy, with little evidence 
for heterogeneity between trials (odds ratio 1·47, 95% CI 1·16–1·85, p=0·001; I²=10%; 
appendix).27
Interpretation
ICSS contributes about a third of the total evidence from randomised trials of stenting 
versus endarterectomy for symptomatic carotid stenosis, measured by statistical weight 
(appendix). We found overall the balance between procedure-related risks and long-term 
eﬃ  cacy in preventing stroke favours endarterectomy. At the individual level, however, the 
data show that this diﬀ erence is caused by an excess in non-disabling procedural strokes 
associated with stenting,22 and did not seem to translate into lesser functional ability in 
the long term in patients who received stents. Moreover, this excess risk seemed to be 
limited to elderly patients (70 years or older).7,22 The choice between stenting and 
endarterectomy, therefore, should take into account the diﬀ erent procedure-related risks 
for the two approaches in individual patients. 
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procedure matters more than individual total experience 
or centre volumes.24
This study has several limitations. First, carotid stenting 
was a relatively new procedure when ICSS started. Since 
that time experience with the procedure has increased 
and new cerebral protection systems exerting ﬂ ow arrest 
or reversal have become available that might more 
eﬀ ectively prevent procedural stroke than the distal 
ﬁ lter-type devices that were mainly used in ICSS.25 
Evidence also indicates, however, that the risks associated 
with endarterectomy have declined over the past few 
years.26 Second, we are unable to account for causes (eg, 
dementia) of functional decline over time, as measured 
by the modiﬁ ed Rankin scale, other than the endpoint 
outcomes events measured in the trial. Third, the 
modiﬁ ed Rankin scale is not a precise measure of the 
level of independence, and we cannot rule out subtle 
diﬀ erences in functional outcome or subjective perception 
of wellbeing between the two treatment groups. Fourth, 
the trial was not powered to detect variations in treatment 
eﬀ ects between subgroups of patients.
Overall we found that stenting and endarterectomy are 
durable procedures that are equally eﬀ ective in 
preventing severe strokes that lead to disability or death 
(panel). Stenting has the disadvantage of causing more 
minor non-disabling strokes in the procedural period 
and possibly in the long term. This feature, however, 
must be weighed against the increased risk of procedural 
myocardial infarction, cranial nerve palsy, and access-site 
haematoma associated with endarterectomy.3–6 The 
modiﬁ ed Rankin scale scores suggested similar 
short-term and long-term functional outcomes with the 
two treatments. The choice between stenting and 
endarterec tomy should take into account the diﬀ erent 
procedure-related risks in line with other characteristics 
of individual patients.
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